Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Short Interest Update

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) was the recipient of a significant decline in short interest in the month of July. As of July 15th, there was short interest totaling 920 shares, a decline of 39.0% from the June 30th total of 1,509 shares. Based on an average trading volume of 1,787 shares, the short-interest ratio is presently 0.5 days. Currently, 0.1% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Addex Therapeutics in a research report on Monday, July 6th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Addex Therapeutics Trading Up 0.2%

Shares of ADXN stock opened at $5.60 on Friday. Addex Therapeutics has a 1 year low of $5.04 and a 1 year high of $12.05. The firm’s 50 day moving average is $6.17 and its 200-day moving average is $6.76. The firm has a market capitalization of $6.89 million, a price-to-earnings ratio of -0.94 and a beta of 1.50.

Addex Therapeutics Company Profile

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.